STAT+: Your sepsis algorithm shouldn’t require a time machine
You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox every Wednesday.
The verdict is in: “Health care” will remain two words instead of one at STAT. You can click here to read more about the decision and what STAT readers on both sides of the issue said in our survey.
You know what else is two words? Ice cream. I got an ice cream maker at a garage sale over the weekend. Send your best ice cream recipes, AI story tips, and your questions to aiprognosis@statnews.com
OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations
The American College of Obstetricians and Gynecologists has released a recommended vaccine schedule for pregnant people, one that diverges from the advice currently offered by the Centers for Disease Control and Prevention.
ACOG is recommending four vaccines be routinely administered during pregnancy, with several other vaccines recommended under certain circumstances. The new schedule is endorsed by 13 medical societies and health organizations.
STAT+: Hope for Kendall Square’s lab market
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. In today’s news, we have: pricing conundrums, lab demand, and drug shortages.
The need-to-know this morning
- Sanofi said it was halting a Phase 3 study of its drug riliprubart in a rare autoimmune disease after an interim analysis showed the therapy was not effective. It’s the latest blow to the French firm’s R&D efforts, which new CEO Belén Garijo has been brought in to revitalize.
- Parabilis Medicines, a developer of cancer medicines, raised $670 million in an initial public offering. It’s the largest-ever biotech IPO, topping obesity drugmaker Kailera Therapeutics’ $625 million debut in April.
European countries at odds over drug-pricing policies
In Europe, countries are grappling with what to do about drug prices as they contend with conflicting pressures. Aging populations and growing rates of chronic disease are straining their budgets, but, at the same, the U.S. and drugmakers are demanding they pay more for medicines.
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is maple cinnamon French toast, a pantry favorite. Remember that no prescription is required — so no need to reach for your abacus to calculate a co-pay or rebate. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day, and please do stay in touch. …
The number of prescription drug shortages in the U.S. fell by 23% last year, marking the second consecutive year of declines and the lowest level since 2017, according to a new analysis that otherwise found troubling signs about medicines that are in short supply, STAT says. For instance, the average drug shortage lasted 5.3 years, exceeding the 4.3 years seen in 2024 and greatly outpacing the average two-year shortage experienced in 2019. Moreover, nearly two-thirds of out-of-stock medicines were in short supply for more than three years, and 39% were unavailable for more than five years. Meanwhile, the 75 drugs that were in short supply last year spanned 130 therapeutic categories, indicating that shortages affected a wide range of diseases and patient populations.
In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting pharma companies and patients across the continent — and testing the influence of the U.S., STAT explains. In the U.K., after a pressure campaign from both pharma companies and the Trump administration, the government has adopted more industry-friendly policies while also simply promising to spend more on medicines. Germany, another of the continent’s biggest markets, is headed in the opposite direction. Facing growing deficits in its health budget, the government has proposed moves that would cut spending and increase the fees the industry has to pay.
The Download: the “steroid olympics” and a safer Mythos
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology.
The “steroid olympics” were a circus—and a window into our culture
—Amit Katwala
A couple of weeks ago, at a $50 million arena built in a casino parking lot in Las Vegas, I witnessed a libertarian thought experiment come to life. The inaugural Enhanced Games were the first sporting competition where participants were encouraged to take performance-enhancing drugs.
For supporters of the event, the Enhanced Games offered a glimpse of a future in which medical advances push the human race to new heights—and they never have to get old. As I watched the games unfold, two questions bounced around my head: were they right? And what does that mean for the rest of us?
Read the full story to understand the answers.
MIT Technology Review Narrated: a reality check on the AI jobs hysteria
Despite the growing hysteria over AI’s threat to white-collar jobs, there’s still scant evidence that the technology has had a large-scale impact on the labor market.
Analysis of US labor data shows that unemployment in occupations most exposed to AI is actually lower than in less-exposed jobs. There are also no signs that large numbers of workers are shifting from AI-threatened professions into supposedly safer manual-labor jobs.
It’s true that things aren’t great in the job market. But the reason isn’t simply the rise of AI.
—David Rotman
This is our latest story to be turned into an MIT Technology Review Narrated podcast, which we publish each week on Spotify and Apple Podcasts. Just navigate to MIT Technology Review Narrated on either platform, and follow us to get all our new content as it’s released.
The must-reads
I’ve combed the internet to find you today’s most fun/important/scary/fascinating stories about technology.
1 Anthropic has released a “safe” version of Mythos
It promises it has enough guardrails and user limitations to be safe. (BBC)
+ It has a price tag twice as high as the previous flagship system. (NYT $)
+ Anthropic previously claimed Mythos was too dangerous to release. (CNBC)
+ But critics suspect that was a marketing play. (Guardian)
+ Selective access has become a key strategy for AI labs. (Axios)
2 Seattle has banned new data centers for a year
It’s the largest US city to have passed such a moratorium.(Guardian)
+ Its biggest tech firm, Amazon, has tried to stop the ban. (The Verge)
+ The movement to stop data centers is growing. (NYT $)
3 Democratic senators are pushing for a military AI restriction law
They want a human commander to have the final say. (Gizmodo)
+ But humans in the loop in an AI war is an illusion. (MIT Technology Review)
4 SpaceX plans to launch space data center tests by late 2027
Orbital compute is central to the company’s growth pitch. (Reuters $)
+ It’s also shared new designs for its space data centers. (BI)
+ We’d need these four things to put them in orbit. (MIT Technology Review)
5 China has been accused of escalating AI espionage
A report claims Beijing is hacking tech firms to catch up with the US. (CNBC)
+ There are no winners in a US-China AI arms race. (MIT Technology Review)
6 The Trump family has made about $2.3 billion from crypto
While investors lost about the same amount. (Gizmodo)
+ The Trumps risked next-to-nothing on their crypto ventures. (Reuters $)
7 Apple isn’t launching Siri AI in the European Union
It’s blaming EU interoperability requirements. (The Verge)
+Brussels says Apple didn’t try to find a compliance solution. (Reuters $)
8 China’s new drone rules have spooked its thriving industry
Drone firms face new commercial barriers. (Financial Times $)
+ China’s drone sector leads the world. (NYT $)
9 A judge has cancelled a trial after finding both legal teams used AI
The case descended into GenAI tools arguing against each other. (404 Media)
+ Courts have been flooded with AI-generated lawsuits. (MIT Technology Review)
10 The dinosaur-killing asteroid created a thriving new ecosystem
Microscopic life flourished in the extended heat. (New Scientist $)
Quote of the day
“AI technologies today are designed by and for WEIRD societies—Western, educated, industrialized, rich, and democratic.”
—Aditya Vashistha, an assistant professor at Cornell University, tells Rest of World why AI systems don’t serve global needs.
One More Thing
Why the definition of design might need a change
The word “design” once carried a far wider set of meanings than it does today. They ranged from the literal and material (like tracing) through the tactical (to contrive and achieve a goal) to the organizational and institutional—the “designation” of people and objects.
Over centuries, as designing became increasingly separated from making, that broader understanding faded. But now there is a growing case for reclaiming the word’s original sense: not just the search for a more beautiful shape, but the shaping of a more beautiful and sustainable world.
Find out why we should retool the word “design.”
—Nicholas de Monchaux
We can still have nice things
A place for comfort, fun, and distraction to brighten up your day. (Got any ideas? Drop me a line.)
+ This history of humanity’s search for alien life is fascinating.
+ Watch a damaged painting slowly return to life in this art restoration video.
+ Admire young stars across every stage of cosmic formation in this stunning space picture of the month.
+ Daredevil divers have captured the first-ever underwater footage of an adult great white in the Mediterranean Sea.

